fluvoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1230	54739-18-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fluvoxamine fluvoxamine maleate depromel	A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19. Molecular weight: 318.34 Formula: C15H21F3N2O2 CLOGP: 2.77 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 56.84 ALOGS: -4.64 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fluvoxamine
fluvoxamine maleate
depromel

A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.

Molecular weight: 318.34
Formula: C15H21F3N2O2
CLOGP: 2.77
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 56.84
ALOGS: -4.64
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14.87 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	53 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	31.95 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 5, 1994	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	344.34	18.75	243	6493	228888	63253398
Myoglobin urine present	283.86	18.75	52	6684	720	63481566
Serotonin syndrome	218.43	18.75	90	6646	28592	63453694
Toxic encephalopathy	194.88	18.75	57	6679	6522	63475764
Amylase increased	174.91	18.75	52	6684	6293	63475993
Suicide attempt	159.33	18.75	92	6644	60826	63421460
Troponin increased	158.84	18.75	54	6682	10067	63472219
Blood creatine phosphokinase increased	152.01	18.75	71	6665	30359	63451927
Intentional overdose	145.11	18.75	93	6643	74059	63408227
Blood potassium increased	131.04	18.75	55	6681	18254	63464032
Intentional self-injury	125.38	18.75	59	6677	25628	63456658
Blood lactate dehydrogenase increased	121.85	18.75	56	6680	23060	63459226
Toxicity to various agents	81.79	18.75	115	6621	247135	63235151
Neuroleptic malignant syndrome	75.62	18.75	33	6703	12023	63470263
Drug abuse	73.20	18.75	61	6675	72457	63409829
Somnolence	72.68	18.75	92	6644	178593	63303693
Alanine aminotransferase increased	68.90	18.75	69	6667	103701	63378585
Suicidal ideation	51.85	18.75	47	6689	62374	63419912
Mydriasis	50.84	18.75	25	6711	11931	63470355
Electrocardiogram QT prolonged	45.90	18.75	43	6693	59487	63422799
Sopor	43.76	18.75	28	6708	22136	63460150
Oscillopsia	42.16	18.75	8	6728	135	63482151
Drug level increased	40.67	18.75	27	6709	22709	63459577
Schizophrenia	39.91	18.75	20	6716	9932	63472354
Galactorrhoea	38.36	18.75	15	6721	4140	63478146
Overdose	35.68	18.75	52	6684	115026	63367260
Obsessive-compulsive disorder	35.18	18.75	14	6722	4046	63478240
Hypotension	33.64	18.75	83	6653	272521	63209765
Tremor	30.26	18.75	52	6684	132187	63350099
Anxiety	29.80	18.75	69	6667	217472	63264814
Extrapyramidal disorder	29.28	18.75	18	6718	13266	63469020
Completed suicide	29.12	18.75	54	6682	145619	63336667
Agitation	26.19	18.75	32	6704	59725	63422561
Restlessness	26.07	18.75	23	6713	29430	63452856
Psychotic disorder	24.61	18.75	21	6715	25691	63456595
Torsade de pointes	24.22	18.75	16	6720	13335	63468951
Alice in wonderland syndrome	23.82	18.75	4	6732	32	63482254
Drug screen false positive	23.29	18.75	7	6729	877	63481409
Akinesia	23.03	18.75	8	6728	1585	63480701
Mental disorder	22.46	18.75	20	6716	25899	63456387
Anaemia folate deficiency	21.64	18.75	5	6731	225	63482061
Personality disorder	21.32	18.75	11	6725	5800	63476486
Congestive cardiomyopathy	20.68	18.75	11	6725	6171	63476115
Dysarthria	20.57	18.75	24	6712	42687	63439599
Aspiration of gastric residual	19.63	18.75	3	6733	12	63482274
Altered state of consciousness	19.00	18.75	18	6718	25212	63457074
Miosis	18.90	18.75	11	6725	7342	63474944

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Loss of libido	211.93	22.45	55	5897	2497	34948482
Drug interaction	158.78	22.45	193	5759	225753	34725226
Apathy	153.87	22.45	54	5898	6878	34944101
Sedation	142.13	22.45	70	5882	20936	34930043
Schizophrenia	131.37	22.45	51	5901	8615	34942364
Psychotic disorder	126.44	22.45	68	5884	24384	34926595
Suicidal ideation	121.18	22.45	79	5873	40309	34910670
Serotonin syndrome	99.03	22.45	54	5898	19879	34931100
Neuroleptic malignant syndrome	76.58	22.45	44	5908	17890	34933089
Persecutory delusion	76.53	22.45	25	5927	2555	34948424
Drug level increased	75.60	22.45	47	5905	22049	34928930
Encephalitis toxic	70.92	22.45	15	5937	273	34950706
Antipsychotic drug level increased	66.64	22.45	25	5927	3840	34947139
Orthostatic hypotension	66.39	22.45	46	5906	25873	34925106
Salivary hypersecretion	65.02	22.45	31	5921	8613	34942366
Social avoidant behaviour	64.28	22.45	23	5929	3091	34947888
Delirium	62.34	22.45	55	5897	43936	34907043
Aggression	61.88	22.45	52	5900	38912	34912067
Intentional overdose	60.68	22.45	54	5898	43620	34907359
Tardive dyskinesia	60.12	22.45	26	5926	5764	34945215
Enuresis	58.64	22.45	20	5932	2333	34948646
Weight increased	57.76	22.45	75	5877	92958	34858021
Overdose	55.89	22.45	73	5879	90986	34859993
Suicide attempt	55.60	22.45	49	5903	39067	34911912
Catatonia	50.33	22.45	22	5930	5003	34945976
Obsessive-compulsive disorder	48.18	22.45	22	5930	5542	34945437
Depression	46.35	22.45	69	5883	97029	34853950
Sopor	44.51	22.45	27	5925	12109	34938870
Obesity	40.54	22.45	26	5926	12852	34938127
Completed suicide	38.83	22.45	64	5888	98104	34852875
Sexual relationship change	38.01	22.45	6	5946	17	34950962
Mental impairment	37.94	22.45	23	5929	10299	34940680
Toxicity to various agents	37.76	22.45	96	5856	200266	34750713
Cardiac dysfunction	36.26	22.45	14	5938	2324	34948655
Sexual dysfunction	33.85	22.45	18	5934	6285	34944694
Anxiety	31.74	22.45	59	5893	99369	34851610
Hanging	31.29	22.45	7	5945	167	34950812
Orgasmic sensation decreased	30.93	22.45	6	5946	69	34950910
Cyclothymic disorder	29.64	22.45	6	5946	87	34950892
Obsessive thoughts	29.37	22.45	9	5943	746	34950233
Coma scale abnormal	28.99	22.45	14	5938	3994	34946985
Respiratory fatigue	28.86	22.45	6	5946	100	34950879
Antipsychotic drug level above therapeutic	28.85	22.45	10	5942	1223	34949756
Premature ejaculation	27.55	22.45	6	5946	126	34950853
Intentional self-injury	27.41	22.45	21	5931	13750	34937229
Neonatal behavioural syndrome	27.28	22.45	6	5946	132	34950847
Motor developmental delay	26.15	22.45	8	5944	660	34950319
Hypothermia	25.00	22.45	18	5934	10730	34940249
Distributive shock	24.89	22.45	9	5943	1245	34949734
Akathisia	24.60	22.45	16	5936	8093	34942886
Genital hypoaesthesia	24.21	22.45	6	5946	225	34950754
Tic	23.87	22.45	10	5942	2048	34948931
Labelled drug-drug interaction medication error	23.81	22.45	20	5932	14919	34936060
Irritability	23.81	22.45	25	5927	24665	34926314
Somnolence	23.81	22.45	56	5896	111060	34839919
Impulsive behaviour	23.40	22.45	10	5942	2152	34948827
Brain injury	23.38	22.45	14	5938	6128	34944851
Heat stroke	23.25	22.45	8	5944	957	34950022
Bradycardia	23.11	22.45	44	5908	75374	34875605

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	407.39	17.13	382	10540	414801	79318665
Serotonin syndrome	291.65	17.13	136	10786	44891	79688575
Myoglobin urine present	242.02	17.13	49	10873	898	79732568
Intentional overdose	185.76	17.13	137	10785	105823	79627643
Suicide attempt	174.80	17.13	120	10802	82812	79650654
Toxic encephalopathy	135.31	17.13	53	10869	11387	79722079
Intentional self-injury	133.24	17.13	72	10850	32347	79701119
Troponin increased	127.14	17.13	59	10863	19196	79714270
Blood creatine phosphokinase increased	123.77	17.13	89	10833	66001	79667465
Neuroleptic malignant syndrome	121.10	17.13	64	10858	27495	79705971
Amylase increased	118.88	17.13	48	10874	11161	79722305
Loss of libido	106.88	17.13	31	10891	2654	79730812
Toxicity to various agents	105.91	17.13	199	10723	421341	79312125
Suicidal ideation	103.83	17.13	85	10837	76255	79657211
Sedation	99.70	17.13	71	10851	51824	79681642
Blood potassium increased	87.95	17.13	53	10869	29222	79704244
Drug level increased	84.92	17.13	58	10864	39593	79693873
Overdose	80.51	17.13	112	10810	184094	79549372
Psychotic disorder	80.33	17.13	57	10865	41345	79692121
Apathy	80.21	17.13	38	10884	12939	79720527
Blood lactate dehydrogenase increased	76.17	17.13	54	10868	39116	79694350
Somnolence	74.28	17.13	124	10798	238857	79494609
Sopor	72.38	17.13	49	10873	32961	79700505
Schizophrenia	71.07	17.13	37	10885	15403	79718063
Encephalitis toxic	68.02	17.13	14	10908	279	79733187
Obsessive-compulsive disorder	64.97	17.13	26	10896	5901	79727565
Catatonia	64.62	17.13	29	10893	8727	79724739
Completed suicide	62.74	17.13	117	10805	245650	79487816
Salivary hypersecretion	62.37	17.13	33	10889	14191	79719275
Drug abuse	60.96	17.13	92	10830	162599	79570867
Enuresis	60.87	17.13	21	10901	3155	79730311
Aggression	59.50	17.13	52	10870	50906	79682560
Anxiety	51.00	17.13	108	10814	248404	79485062
Tremor	48.50	17.13	85	10837	169998	79563468
Antipsychotic drug level increased	48.04	17.13	21	10901	5936	79727530
Orthostatic hypotension	44.03	17.13	46	10876	56118	79677348
Agitation	42.56	17.13	60	10862	99655	79633811
Tardive dyskinesia	42.07	17.13	23	10899	10548	79722918
Galactorrhoea	39.98	17.13	16	10906	3630	79729836
Akathisia	39.79	17.13	24	10898	13235	79720231
Delirium	37.72	17.13	52	10870	84575	79648891
Oscillopsia	37.13	17.13	8	10914	200	79733266
Extrapyramidal disorder	36.70	17.13	28	10894	22651	79710815
Obsessive thoughts	36.04	17.13	11	10911	1121	79732345
Mydriasis	35.85	17.13	25	10897	17618	79715848
Dyspnoea	34.60	17.13	40	10882	856985	78876481
Hanging	33.26	17.13	7	10915	156	79733310
Sexual relationship change	33.08	17.13	5	10917	13	79733453
Pain	32.77	17.13	29	10893	703773	79029693
Mental impairment	31.90	17.13	24	10898	19012	79714454
Cyclothymic disorder	31.23	17.13	7	10915	211	79733255
Arthralgia	31.17	17.13	20	10902	571783	79161683
Electrocardiogram QT prolonged	30.85	17.13	49	10873	90337	79643129
Alanine aminotransferase increased	30.28	17.13	68	10854	162502	79570964
Distributive shock	30.19	17.13	12	10910	2675	79730791
Irritability	29.24	17.13	32	10890	41112	79692354
Cardiac dysfunction	28.34	17.13	13	10909	4111	79729355
Orgasmic sensation decreased	27.50	17.13	5	10917	50	79733416
Semen volume decreased	26.22	17.13	5	10917	66	79733400
Premature ejaculation	26.15	17.13	5	10917	67	79733399
Rhabdomyolysis	26.13	17.13	49	10873	103082	79630384
Labelled drug-drug interaction medication error	25.99	17.13	25	10897	27625	79705841
Antipsychotic drug level above therapeutic	25.87	17.13	10	10912	2070	79731396
Parkinsonism	25.79	17.13	20	10902	16564	79716902
Gaze palsy	25.56	17.13	11	10911	2994	79730472
Psychomotor skills impaired	25.39	17.13	13	10909	5224	79728242
Respiratory fatigue	24.57	17.13	6	10916	264	79733202
Activation syndrome	24.25	17.13	6	10916	279	79733187
Mania	24.10	17.13	20	10902	18240	79715226
Drug reaction with eosinophilia and systemic symptoms	23.55	17.13	36	10886	64208	79669258
Sexual dysfunction	23.16	17.13	14	10908	7749	79725717
Restlessness	22.89	17.13	30	10892	46462	79687004
Myoclonus	22.29	17.13	23	10899	27637	79705829
Bradycardia	22.28	17.13	54	10868	135503	79597963
Hallucination	22.04	17.13	41	10881	85704	79647762
Coma scale abnormal	21.72	17.13	14	10908	8664	79724802
Febrile neutropenia	21.61	17.13	3	10919	230996	79502470
Alice in wonderland syndrome	21.49	17.13	4	10918	46	79733420
Inappropriate antidiuretic hormone secretion	21.42	17.13	22	10900	26291	79707175
Altered state of consciousness	21.15	17.13	28	10894	43794	79689672
Genital hypoaesthesia	21.04	17.13	5	10917	196	79733270
Hypotension	20.99	17.13	117	10805	440200	79293266
Acanthosis nigricans	20.97	17.13	5	10917	199	79733267
Hyperprolactinaemia	20.92	17.13	11	10911	4665	79728801
Weight increased	20.74	17.13	84	10838	277302	79456164
Brain injury	20.37	17.13	15	10907	11502	79721964
Diarrhoea	20.32	17.13	58	10864	880431	78853035
Drug screen false positive	19.97	17.13	7	10915	1102	79732364
Impulsive behaviour	19.49	17.13	9	10913	2891	79730575
Anaemia folate deficiency	18.90	17.13	5	10917	304	79733162
Aspiration of gastric residual	18.86	17.13	3	10919	12	79733454
Hypothermia	18.48	17.13	19	10903	22727	79710739
Akinesia	18.35	17.13	9	10913	3303	79730163
Delusion	18.32	17.13	18	10904	20405	79713061
Negativism	17.68	17.13	6	10916	857	79732609
Self-injurious ideation	17.55	17.13	9	10913	3629	79729837
Depressed level of consciousness	17.50	17.13	40	10882	96612	79636854

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AB08	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Selective serotonin reuptake inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:50949	SSRI
FDA EPC	N0000175696	Serotonin Reuptake Inhibitor
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065689	Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D017367	Selective Serotonin Reuptake Inhibitors
MeSH PA	D018490	Serotonin Agents
MeSH PA	D014149	Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Social phobia	indication	25501002	DOID:11257
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Posttraumatic stress disorder	off-label use	47505003	DOID:2055
Bipolar affective disorder, current episode depression	off-label use	191627008	DOID:3312
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Upper gastrointestinal hemorrhage	contraindication	37372002
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Epilepsy	contraindication	84757009	DOID:1826
Hyponatremia	contraindication	89627008
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Disease of liver	contraindication	235856003	DOID:409
Serotonin syndrome	contraindication	371089000
Breastfeeding (mother)	contraindication	413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.36	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	8.51	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.95	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	8.84	CHEMBL
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		Ki	5.07	WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.44	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT	INHIBITOR	Ki	8.19	IUPHAR
Sigma non-opioid intracellular receptor 1	Membrane receptor		SGMR1_RAT		Ki	7.44	CHEMBL
Sigma intracellular receptor 2	Unclassified		SGMR2_RAT		Ki	5.07	CHEMBL

External reference:

ID	Source
4023976	VUID
N0000021981	NUI
D00824	KEGG_DRUG
61718-82-9	SECONDARY_CAS_RN
4020892	VANDF
4023976	VANDF
C0085228	UMLSCUI
CHEBI:5138	CHEBI
FVX	PDB_CHEM_ID
CHEMBL814	ChEMBL_ID
DB00176	DRUGBANK_ID
CHEMBL1409	ChEMBL_ID
D016666	MESH_DESCRIPTOR_UI
5324346	PUBCHEM_CID
7189	IUPHAR_LIGAND_ID
3879	INN_ID
O4L1XPO44W	UNII
203143	RXNORM
40916	MMSL
4758	MMSL
d03804	MMSL
003633	NDDF
003634	NDDF
116522003	SNOMEDCT_US
372905008	SNOMEDCT_US
96213009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2848	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	21 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2848	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	21 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2849	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	21 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2849	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	21 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1670	TABLET, FILM COATED	25 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1670	TABLET, FILM COATED	25 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1671	TABLET, FILM COATED	50 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1671	TABLET, FILM COATED	50 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1672	TABLET, FILM COATED	100 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1672	TABLET, FILM COATED	100 mg	ORAL	ANDA	34 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-175	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-175	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-176	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-176	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-270	TABLET	25 mg	ORAL	NDA	11 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-683	TABLET, COATED	50 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5988	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0164	TABLET	25 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0165	TABLET	50 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0166	TABLET	100 mg	ORAL	ANDA	32 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-158	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-158	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-159	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-159	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-160	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-160	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8018	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2337	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68151-0637	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7219	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections